Invention Grant
- Patent Title: Use of pridopidine for the treatment of fragile X syndrome
-
Application No.: US16514167Application Date: 2019-07-17
-
Publication No.: US11234973B2Publication Date: 2022-02-01
- Inventor: Michael Hayden , Mahmoud Abdulhossein Pouladi
- Applicant: PRILENIA NEUROTHERAPEUTICS LTD. , NATIONAL UNIVERSITY OF SINGAPORE , AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
- Applicant Address: IL Herzliya; SG Singapore; SG Singapore
- Assignee: PRILENIA NEUROTHERAPEUTICS LTD.,NATIONAL UNIVERSITY OF SINGAPORE,AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
- Current Assignee: PRILENIA NEUROTHERAPEUTICS LTD.,NATIONAL UNIVERSITY OF SINGAPORE,AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
- Current Assignee Address: IL Herzliya; SG Singapore; SG Singapore
- Agency: Pearl Cohen Zedek Latzer Baratz LLP
- Agent Mark S. Cohen
- Main IPC: A61K31/451
- IPC: A61K31/451 ; A61K9/00 ; A61P43/00 ; A61K45/06
Abstract:
The invention provides a method of treating a subject afflicted with fragile X syndrome (FXS) or a FXS related disorder, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to treat the subject.
Public/Granted literature
- US20190336488A1 USE OF PRIDOPIDINE FOR THE TREATMENT OF FRAGILE X SYNDROME Public/Granted day:2019-11-07
Information query
IPC分类:
